ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Vaccines

GSK and CEPI partner on coronavirus vaccine

by Megha Satyanarayana
February 7, 2020 | APPEARED IN VOLUME 98, ISSUE 6

 

To aid the effort to develop a vaccine for the novel coronavirus that originated in China, GlaxoSmithKline has agreed to make its vaccine adjuvant technology available to the nonprofit Coalition for Epidemic Preparedness Innovation. CEPI-funded groups developing vaccines for the virus—such as the University of Queensland—will have access to GSK adjuvants. Adjuvants are chemicals added to vaccines to boost their efficacy.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment